In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BMS bids $4.3bn for Erbitux partner ImClone; withdrawn

Executive Summary

Bristol-Myers Squibb announced plans to acquire public Big Biotech ImClone Systems in a transaction valued at $4.3bn, or seven times ImClone's 2007 sales. ImClone's preliminary response to the offer is that it greatly undervalues the company.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Partial Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register